Klebsiella pneumoniae carbapenemase-producing klebsiella pneumoniae in the intensive care unit: A real challenge to physicians, scientific community, and society

Shock

Volumn 39, Issue 7 SUPPL.1, 2013, Pages 32-37

  Carvalhaes, Cecilia Godoy ^a   Cayô, Rodrigo ^a   Gales, Ana Cristina ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM DERIVATIVE; CARBAPENEMASE; IMIPENEM; MEROPENEM; POLYMYXIN DERIVATIVE; TIGECYCLINE;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM DETECTION; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CARBAPENEMASE PRODUCING KLEBSIELLA PNEUMONIAE; COMMUNITY ACQUIRED PNEUMONIA; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; IN VITRO STUDY; INFECTION PREVENTION; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; PREVALENCE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INTENSIVE CARE UNITS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS;

EID: 84876791052     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e31828faf1f     Document Type: Article

References (55)

1. de Kraker ME, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, Icket C, Kalenic S, Horvatic J, Seifert H, et al.: Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 66(2):398-407, 2011.
2. Evans HL, Lefrak SN, Lyman J, Smith RL, Chong TW, McElearney ST, Schulman AR, Hughes MG, Raymond DP, Pruett TL, et al.: Cost of gramnegative resistance. Crit Care Med 35(1):89-95, 2007.
3. Bradley JS, Garau J, Lode H, Rolston KV, Wilson SE, Quinn JP: Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents 11(2):93-100, 1999. (Pubitemid 29114967)
4. Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K: Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC β-lactamase, and the loss of an outer membrane protein. Antimicrob Agents Chemother 41(3):563-569, 1997. (Pubitemid 27098404)
5. Martinez-Martinez L, Pascual A, Hernandez-Alles S, Alvarez-Díaz D, Suárez AI, Tran J, Benedí VJ, Jacoby GA: Roles of β-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob Agents Chemother 43(7):1669-1673, 1999. (Pubitemid 29331245)
6. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K, Tenover FC: Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 45(4):1151-1161, 2001. (Pubitemid 32230996)
7. Hirsch EB, Tam VH: Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 65(6):1119-1125, 2010.
8. Nordmann P, Cuzon G, Naas T: The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 9(4):228-236, 2009.
9. Smith Moland E, Hanson ND, Herrera VL, Black JA, Lockhart TJ, Hossain A, Johnson JA, Goering RV, Thomson KS: Plasmid-mediated, carbapenemhydrolysing beta-lactamase, KPC-2, in Klebsiella pneumoniae isolates. J Antimicrob Chemother 51(3):711-714, 2003. (Pubitemid 36336168)
10. Lat A, Clock SA, Wu F, Whittier S, Della-Latta P, Fauntleroy K, Jenkins SG, Saiman L, Kubin CJ: Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest. J Clin Microbiol 49(5):1795-1798, 2011.
11. Bratu S, Mooty M, Nichani S, Landman D, Gullans C, Pettinato B, Karumudi U, Tolaney P, Quale J: Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother 49(7):3018-3020, 2005. (Pubitemid 40917631)
12. Carvalhaes CG, Picão RC, Nicoletti AG, Xavier DE, Gales AC: Cloverleaf test (modified Hodge test) for detecting carbapenemase production in Klebsiella pneumoniae: be aware of false positive results. J Antimicrob Chemother 65(2): 249-251, 2010.
13. Endimiani A, Perez F, Bajaksouzian S, Windau AR, Good CE, Choudhary Y, Hujer AM, Bethel CR, Bonomo RA, Jacobs MR: Evaluation of updated interpretative criteria for categorizing Klebsiella pneumoniae with reduced carbapenem susceptibility. J Clin Microbiol 48(12):4417-4425, 2010.
14. Clinical and Laboratory Standard Institute: Performance Standards for Antimicrobial Susceptibility Testing Twentieth Informational Supplement (June 2010 Update). M100S20U, 2010.
15. KPC) variants. J Clin Microbiol 49(2):579-585, 2011.
16. Endimiani A, Hujer KM, Hujer AM, Kurz S, Jacobs MR, Perlin DS, Bonomo RA: Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia? Clin Infect Dis 52(Suppl 4):S373-S383, 2011.
17. Burckhardt I, Zimmermann S: Using matrix-assisted laser desorption ionizationtime of flight mass spectrometry to detect carbapenem resistance within 1 to 2.5 hours. J Clin Microbiol 49(9):3321-3324, 2011.
18. Hrabák J, Walková R, Studentová V, Chudácková E, Bergerová T: Carbapenemase activity detection by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 49(9):3222-3227, 2011.
19. Ecker DJ, Sampath R, Massire C, Blyn LB, Hall TA, Eshoo MW, Hofstadler SA: Ibis T5000: a universal biosensor approach for microbiology. Nat Rev Microbiol 6(7):553-558, 2008. (Pubitemid 351850978)
20. Endimiani A, Hujer AM, Hujer KM, Gatta JA, Schriver AC, Jacobs MR, Rice LB, Bonomo RA: Evaluation of a commercial microarray system for detection of SHV-, TEM-, CTX-M-, and KPC-type beta-lactamase genes in gramnegative isolates. J Clin Microbiol 48(7):2618-2622, 2010.
21. Bradford PA, Bratu S, Urban C, Visalli M, Mariano N, Landman D, Rahal JJ, Brooks S, Cebular S, Quale J: Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitorresistant TEM-30 beta-lactamases in New York City. Clin Infect Dis 39(1): 55-60, 2004. (Pubitemid 38879549)
22. Nordmann P, Naas T, Poirel L: Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17(10):1791-1798, 2011.
23. Weisenberg SA, Morgan DJ, Espinal-Witter R, Larone DH: Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem. Diagn Microbiol Infect Dis 64(2):233-235, 2009.
24. Daikos GL, Markogiannakis A: Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect 17(8):1135-1141, 2011.
25. Bulik CC, Christensen H, Li P, Sutherland CS, Nicolau DP, Kuti JL: Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 54(2):804-810, 2010.
26. Ho VP, Jenkins SG, Afaneh CI, Turbendian HK, Nicolau DP, Barie PS: Use of meropenem by continuous infusion to treat a patient with a Bla(kpc-2)Y positive Klebsiella pneumoniae blood stream infection. Surg Infect (Larchmt) 12(4):325-327, 2011.
27. Bulik CC, Nicolau DP: In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 54(10):4112-4115, 2010.
28. Bulik CC, Nicolau DP: Double-carbapenem therapy for carbapenemaseproducing Klebsiella pneumoniae. Antimicrob Agents Chemother 55(6): 3002-3004, 2011.
29. Zavascki AP, Carvalhaes CG, Picão RC, Gales AC. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 8(1):71-93, 2010.
30. Schafer JJ, Goff DA: Establishing the role of tigecycline in an era of antimicrobial resistance. Expert Rev Anti Infect Ther 6(5):557-567, 2008.
31. Cunha BA: Pharmacokinetic considerations regarding tigecycline for multidrugresistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis. J Clin Microbiol 47(5):1613, 2009.
32. Zarkotou O, Pournaras S, Voulgari E, Chrysos G, Prekates A, Voutsinas D, Themeli-Digalaki K, Tsakris A: Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study. J Clin Microbiol 48:2271, 2010.
33. Neuner EA, Yeh JY, Hall GS, Sekeres J, Endimiani A, Bonomo RA, Shrestha NK, Fraser TG, van Duin D: Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis 69(4):357-362, 2011.
34. Elemam A, Rahimian J, Mandell W: Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin Infect Dis 49(2):271-274, 2009.
35. Infectious Diseases Society of America: The 10 × '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 50(8):1081-1083, 2010.
36. Kitchel B, Rasheed JK, Patel JB, Srinivasan A, Navon-Venezia S, Carmeli Y, Brolund A, Giske CG: Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 53(8):3365-3370, 2009.
37. PC-2-carrying Klebsiella pneumoniae in Greece (2009-10). J Antimicrob Chemother 66(7):1510-1513, 2011.
38. Navon-Venezia S, Leavitt A, Schwaber MJ, Rasheed JK, Srinivasan A, Patel JB, Carmeli Y, Israeli KPC Kpn Study Group: First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob Agents Chemother 53(2):818-820, 2009.
39. Woodford N, Tierno PM Jr, Young K, Tysall L, Palepou MF, Ward E, Painter RE, Suber DF, Shungu D, Silver LL, et al.: Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center. Antimicrob Agents Chemother 48(12): 4793-4799, 2004. (Pubitemid 39577686)
40. Gregory CJ, Llata E, Stine N, Gould C, Santiago LM, Vazquez GJ, Robledo IE, Srinivasan A, Goering RV, Tomashek KM: Outbreak of carbapenemresistant Klebsiella pneumoniae in Puerto Rico associated with a novel carbapenemase variant. Infect Control Hosp Epidemiol 31(5):476-484, 2010.
41. Tenover FC, Kalsi RK, Williams PP, Carey RB, Stocker S, Lonsway D, Rasheed JK, Biddle JW, McGowan JE Jr, Hanna B: Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis 12(8):1209-1213, 2006.
42. Moquet O, Bouchiat C, Kinana A, Seck A, Arouna O, Bercion R, Breurec S, Garin B: Class D OXA-48 carbapenemase in multidrug-resistant enterobacteria, Senegal. Emerg Infect Dis 17(1):143-144, 2011.
43. Canton R, Ruiz-Garbajosa P: Co-resistance: an opportunity for the bacteria and resistance genes. Curr Opin Pharmacol 11(5):477-485, 2011.
44. Schwaber MJ, Lev B, Israeli A, Solter E, Smollan G, Rubinovitch B, Shalit I, Carmeli Y, Israel Carbapenem-Resistant Enterobacteriaceae Working Group: Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 52(7):848-855, 2011.
45. Andersson DI: The biological cost of mutational antibiotic resistance: any practical conclusions? Curr Opin Microbiol 9(5):461-465, 2006. (Pubitemid 44397630)
46. Besier S, Ludwig A, Brade V, Wichelhaus TA: Compensatory adaptation to the loss of biological fitness associated with acquisition of fusidic acid resistance in Staphylococcus aureus. Antimicrob Agents Chemother 49(4): 1426-1431, 2005. (Pubitemid 40463372)
47. Kugelberg E, Lofmark S, Wretlind B, Andersson DI: Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa. J Antimicrob Chemother 55(1):22-30, 2005. (Pubitemid 40192610)
48. Tsai YK, Fung CP, Lin JC, Chen JH, Chang FY, Chen TL, Siu LK: Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence. Antimicrob Agents Chemother 55(4): 1485-1493, 2011.
49. Bialek S, Lavigne JP, Chevalier J, Marcon E, Leflon-Guibout V, Davin A, Moreau R, Pagès JM, Nicolas-Chanoine MH: Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model. Antimicrob Agents Chemother 54(10): 4373-4378, 2010.
50. Bachman MA, Oyler JE, Burns SH, Caza M, Lépine F, Dozois CM, Weiser JN: Klebsiella pneumoniae yersiniabactin promotes respiratory tract infection through evasion of lipocalin 2. Infect Immun 79(8):3309-3316, 2011.
51. Monier JM, Demanèche S, Delmont TO, Mathieu A, Vogel TM, Simonet P: Metagenomic exploration of antibiotic resistance in soil. Curr Opin Microbiol 14(3):229-235, 2011.
52. Jousset A: Ecological and evolutive implications of bacterial defences against predators. Environ Microbiol 14(8):1830-1843, 2012.
53. Nordmann P, Poirel L: Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. J Antimicrob Chemother 56(3):463-469, 2005. (Pubitemid 41264121)
54. KPC? Presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011; Chicago, Illinois.
55. Grad YH, Lipsitch M, Feldgarden M, Arachchi HM, Cerqueira GC, Fitzgerald M, Godfrey P, Haas BJ, Murphy CI, Russ C, et al.: Genomic epidemiology of the Escherichia coli O104:H4 outbreaks in Europe. Proc Natl Acad Sci U S A 109(8):3065-3070, 2011.